(2R)-2-[(2-methoxy-5-{[(1R)-1-phenylethyl]sulfanyl}-[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol | 911715-89-4

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: (2R)-2-[(2-methoxy-5-{[(1R)-1-phenylethyl]sulfanyl}-[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol
• 英文别名: (2R)-2-[(2-methoxy-5-{[(1R)-1-phenylethyl]thio}[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol；(2R)-2-[[2-methoxy-5-[(1R)-1-phenylethyl]sulfanyl-[1,3]thiazolo[4,5-d]pyrimidin-7-yl]amino]-4-methylpentan-1-ol
• CAS: 911715-89-4
• 化学式: C₂₀H₂₆N₄O₂S₂
• 分子量: 418.584
• InChiKey: IYABMPZWIARKBQ-UKRRQHHQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  134
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  (2R)-2-[(2-methoxy-5-{[(1R)-1-phenylethyl]sulfanyl}-[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol 在 盐酸 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以66%的产率得到
  参考文献：
  名称：

  Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX₃CR1)

  摘要：

  We have developed two parallel series, A and B, of CX(3)CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]-pyrimidine core structure, we were able to achieve compounds with high selectivity for CX(3)CR1 over the closely related CXCR2 receptor. The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with alpha-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h. We show the preparation of the first potent and selective orally available CX(3)CR1 antagonists.

  DOI：

  10.1021/jm3012273
• 作为产物：
  描述：

  (S)-(1-氯乙基)苯 在 盐酸 、 sodium tetrahydroborate 、 N,N-二异丙基乙胺 、 potassium hydroxide 、 sodium nitrite 作用下， 以 水 、 二甲基亚砜 、 乙腈 为溶剂， 生成 (2R)-2-[(2-methoxy-5-{[(1R)-1-phenylethyl]sulfanyl}-[1,3]thiazolo[4,5-d]pyrimidin-7-yl)amino]-4-methylpentan-1-ol
  参考文献：
  名称：

  Substituted 7-Amino-5-thio-thiazolo[4,5-d]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX₃CR1)

  摘要：

  We have developed two parallel series, A and B, of CX(3)CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]-pyrimidine core structure, we were able to achieve compounds with high selectivity for CX(3)CR1 over the closely related CXCR2 receptor. The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with alpha-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h. We show the preparation of the first potent and selective orally available CX(3)CR1 antagonists.

  DOI：

  10.1021/jm3012273

文献信息

• Novel 5,7-Disubstituted [1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 794
  申请人：Nordvall Gunnar

  公开号：US20090124637A1

  公开（公告）日：2009-05-14

  There are disclosed novel 5,7-disubstituted [1,3]thiazolo[4,5-d]pyrimidin-2(3H)-one derivatives of formula (I) [Chemical formula should be inserted here. Please see paper copy] wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined in the specification, and pharmaceutically acceptable salts thereof, together with processes for their preparation, pharmaceutical compositions comprising them and their use in therapy. The compounds of formula (I) are CX 3 CR 1 receptor antagonists and are thereby particularly useful in the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease, cardio- and cerebrovascular atherosclerotic disorders, peripheral artery disease, rheumatoid arthritis, pulmonary diseases such as COPD, asthma or pain.

  本文揭示了新颖的5,7-二取代[1,3]噻唑并[4,5-d]嘧啶-2(3H)-酮衍生物的公式(I) [化学式应在此处插入。请参见纸质复印件]，其中R1、R2、R3、R4和R5如规范中定义的那样，以及其药学上可接受的盐，以及它们的制备方法、包含它们的制剂和它们在治疗中的用途。公式(I)化合物是CX3CR1受体拮抗剂，因此在神经退行性疾病、脱髓鞘疾病、心脑血管动脉粥样硬化性疾病、周围动脉疾病、类风湿性关节炎、COPD、哮喘或疼痛的治疗或预防中特别有用。
• US8088780B2
  申请人：——

  公开号：US8088780B2

  公开（公告）日：2012-01-03
• Substituted 7-Amino-5-thio-thiazolo[4,5-<i>d</i>]pyrimidines as Potent and Selective Antagonists of the Fractalkine Receptor (CX₃CR1)
  作者：Sofia Karlström、Gunnar Nordvall、Daniel Sohn、Andreas Hettman、Dominika Turek、Kristofer Åhlin、Annika Kers、Martina Claesson、Can Slivo、Yvonne Lo-Alfredsson、Carl Petersson、Galina Bessidskaia、Per H. Svensson、Tobias Rein、Eva Jerning、Åsa Malmberg、Charlotte Ahlgen、Colin Ray、Lauri Vares、Vladimir Ivanov、Rolf Johansson

  DOI：10.1021/jm3012273

  日期：2013.4.25

  We have developed two parallel series, A and B, of CX(3)CR1 antagonists for the treatment of multiple sclerosis. By modifying the substituents on the 7-amino-5-thio-thiazolo[4,5-d]-pyrimidine core structure, we were able to achieve compounds with high selectivity for CX(3)CR1 over the closely related CXCR2 receptor. The structure-activity relationships showed that a leucinol moiety attached to the core-structure in the 7-position together with alpha-methyl branched benzyl derivatives in the 5-position displayed promising affinity, and selectivity as well as physicochemical properties, as exemplified by compounds 18a and 24h. We show the preparation of the first potent and selective orally available CX(3)CR1 antagonists.